Provided by Tiger Fintech (Singapore) Pte. Ltd.

VolitionRX

0.4780
-0.0120-2.45%
Volume:69.11K
Turnover:33.53K
Market Cap:46.15M
PE:-1.53
High:0.4970
Open:0.4970
Low:0.4740
Close:0.4900
Loading ...

VolitionRX Price Target Maintained With a $2.50/Share by HC Wainwright & Co.

Dow Jones
·
11 Apr

HC Wainwright Initiates VolitionRx With Buy Rating, $2.50 Price Target

MT Newswires Live
·
08 Apr

VolitionRX Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
08 Apr

VolitionRX Ltd (VNRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances

GuruFocus.com
·
01 Apr

BRIEF-Volitionrx Limited Announces Full Fiscal Year 2024 Financial Results And Business Update

Reuters
·
01 Apr

VolitionRX FY Sales $1.200M Miss $1.796M Estimate

Benzinga
·
01 Apr

VolitionRX Limited Announces Full Fiscal Year 2024 Financial Results and Business Update

THOMSON REUTERS
·
01 Apr

VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update

PR Newswire
·
01 Apr

VolitionRX Is Maintained at Buy by D. Boral Capital

Dow Jones
·
31 Mar

BRIEF-Volition Announces Two Poster Presentations At Esmo's European Lung Cancer Congress 2025

Reuters
·
28 Mar

Volition Announces Two Poster Presentations at Esmo's European Lung Cancer Congress 2025

THOMSON REUTERS
·
28 Mar

Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025

PR Newswire
·
28 Mar

Press Release: Volition to Host Virtual Investor Event on Nu.Q(R) Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025

Dow Jones
·
27 Mar

BRIEF-VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering

Reuters
·
26 Mar

VolitionRX Announces Pricing of up to $2.3 Million Registered Direct Offering

THOMSON REUTERS
·
26 Mar

VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update

PR Newswire
·
25 Mar

VolitionRX Reports Positive Results of Automated Nu.Q Cancer Immunoassay Test in Development

MT Newswires Live
·
21 Mar

VolitionRx reports results from Nu.Q Cancer test

TIPRANKS
·
21 Mar

VolitionRX Is Maintained at Buy by D. Boral Capital

Dow Jones
·
21 Mar

Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer

PR Newswire
·
20 Mar